• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

    1/30/24 10:48:36 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2023 held on January 30, 2024 (the "Meeting"). A total of 5,375,071 common shares of the Company (the "Common Shares") were voted, representing 33.63% of the Company's issued and outstanding Common Shares.

    At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the re-appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration, and the election of each of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Marc Lustig, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company.

    A total of 5,375,071 common shares were voted in connection with the election of the directors as follows:

    DirectorVotes For% of Votes ForVotes Withheld% of Votes Withheld
    Dr. William V. Williams3,487,70499.71%10,2510.29%
    Mr. Jamieson Bondarenko3,302,54394.41%195,4125.59%
    Mr. Marc Lustig3,221,12892.09%276,8277.91%
    Dr. Jane A. Gross3,491,30899.81%6,6470.19%
    Dr. Rebecca Taub3,491,35199.81%6,6040.19%
    Mr. Vaughn C. Embro-Pantalony3,489,39899.76%8,5570.24%
    Mr. Martin E. Schmieg3,486,91399.68%11,0420.32%



    The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company's SEDAR+ profile at www.sedarplus.ca.

    About BriaCell Therapeutics Corp.

    BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

    Safe Harbor

    This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

    Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact Information

    Company Contact:

    William V. Williams, MD

    President & CEO

    1-888-485-6340

    [email protected]

    Media Relations:

    Jules Abraham

    Director of Public Relations

    CORE IR

    917-885-7378

    [email protected]

    Investor Relations Contact:

    CORE IR

    [email protected]



    Primary Logo

    Get the next $BCTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

      2/14/22 6:04:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    SEC Filings

    See more
    • BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

      7/16/25 4:15:57 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BriaCell Therapeutics Corp.

      EFFECT - BriaCell Therapeutics Corp. (0001610820) (Filer)

      7/16/25 12:15:16 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by BriaCell Therapeutics Corp.

      424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)

      7/15/25 9:18:03 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 4:38:08 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Williams William V.

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 3:22:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

      PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. The titles of the poster presentations are listed below. #8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) #3928: Feasibility and Biomarker Validation of an Internation

      7/25/25 7:30:00 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Therapeutics Announces Closing of $15 million Public Offering

      PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or one pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit was sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and of

      7/16/25 4:05:59 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Therapeutics Announces Pricing of $15 million Public Offering

      PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and off

      7/15/25 3:05:01 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/12/24 6:06:07 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/10/24 6:06:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

      SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      12/5/24 7:45:06 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

      PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

      2/5/25 6:15:47 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

      PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

      1/3/25 5:05:00 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

      PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

      12/17/24 4:05:59 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Financials

    Live finance-specific insights

    See more
    • ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

      The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

      7/7/23 8:10:00 AM ET
      $BCTX
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care